Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 5/20 | 0.39 |
| ▸ | SRC | P12931 | 5/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 9/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463424 | 0.81 | BTK (0.50) | BTKIGF1RABL1SRCTNK2 | |
| SCHEMBL3540179 | 0.81 | NUDT1 (0.36) | BTKABL1SRCTNK2NUDT1 | |
| SCHEMBL31391151 | 0.79 | ABL1 (0.43) | BTKABL1SRCTNK2 | |
| SCHEMBL1129368 | 0.79 | NUDT1 (0.34) | BTKABL1SRCTNK2NUDT1 | |
| SCHEMBL12165128 | 0.79 | BTK (0.51) | BTKIGF1RABL1SRCTNK2 | |
| SCHEMBL18956083 | 0.79 | IDO1 (0.34) | BTKIGF1RIDO1 | |
| SCHEMBL13201547 | 0.79 | BTK (0.48) | BTKIGF1RABL1SRCTNK2 | |
| SCHEMBL18099733 | 0.78 | ABL1 (0.53) | BTKABL1SRCTNK2NUDT1 | |
| SCHEMBL31330632 | 0.78 | TNK2 (0.51) | BTKIGF1RABL1SRCTNK2 | |
| SCHEMBL23111989 | 0.78 | TNK2 (0.51) | BTKABL1SRCTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331054-B2 | Perk inhibiting imidazolopyrazine compounds | HIBERCELL, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-11649237-B2 | Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition | OPTIKIRA LLC (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3675858-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | OPTIKIRA LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-110627796-B | Nitrogenous heterocyclic derivative and application thereof in medicine | 北京越之康泰生物医药科技有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021231784-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021041970-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041970-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| CN-110627796-A | Nitrogenous heterocyclic derivative and application thereof in medicine | 北京越之康泰生物医药科技有限公司 | 2019-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649237-B2 | Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition | XBP1, HSPA5, ERN1 | BTK 3770/4885IGF1R 374/4885ABL1 4264/4885 |
| US-12331054-B2 | Perk inhibiting imidazolopyrazine compounds | MAPKAPK2, MAPK4, MAP3K5 | BTK 831/4885IGF1R 515/4885ABL1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.